Suzhou Yongxin Biopharmaceutical

Suzhou Yongxin Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of innovative immune cell therapies for cancer. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) technologies, with a primary emphasis on treating hematological malignancies and exploring applications in solid tumors. Its lead candidate, YX001, is an anti-CD19 CAR-T therapy currently in clinical development for B-cell malignancies. Suzhou Yongxin operates its own GMP-compliant manufacturing facility to ensure the quality and scalability of its cell therapy products. The company aims to address unmet medical needs through the optimization of cell engineering and manufacturing processes.